CIK 0001770121 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | |
|---|---|---|
| Net income (USD) | -244.2 M | -269.5 M |
| Diluted EPS (USD/shares) | -0.96 | -1.43 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-06 | 4 | PRIMARY DOCUMENT | 2026-10-05 |
| 2026-09-08 | 8-K | 8-K items 7.01,9.01 | 2026-09-08 |
| 2026-08-27 | 4 | PRIMARY DOCUMENT | 2026-08-26 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-10 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-10 | 8-K | 8-K items 2.02,9.01 | 2026-08-10 |
| 2026-07-07 | 4 | PRIMARY DOCUMENT | 2026-07-06 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 4 | PRIMARY DOCUMENT | 2026-06-04 |
| 2026-06-05 | 8-K | 8-K items 5.07 | 2026-06-04 |
| 2026-05-21 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-15 | 8-K | 8-K items 8.01 | 2026-05-15 |
| 2026-05-11 | S-8 | S-8 | |
| 2026-05-11 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-11 | 8-K | 8-K items 2.02,9.01 | 2026-05-11 |
| 2026-04-24 | ARS | ARS | 2025-12-31 |
| 2026-04-24 | DEFA14A | DEFA14A | |
| 2026-04-24 | DEF 14A | DEF 14A | 2026-06-04 |
| 2026-04-24 | 8-K | 8-K items 5.02 | 2026-04-22 |
Forms on file (last 1,000): 4 146, 8-K 67, 3 26, 4/A 19, 10-Q 17, SC 13G/A 15, 144 13, SC 13G 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=SANA (0.002 USD), /gw/filings/filings?ticker=SANA&form=8-K, /gw/filings/facts?ticker=SANA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange